Cart
sales@molnova.com
PBRM1-BD2-IN-7
CAS No. 2819989-68-7
PBRM1-BD2-IN-7( —— )
Catalog No. M35348 CAS No. 2819989-68-7
PBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 178 | Get Quote |
|
| 5MG | 256 | Get Quote |
|
| 10MG | 375 | Get Quote |
|
| 25MG | 545 | Get Quote |
|
| 50MG | 767 | Get Quote |
|
| 100MG | 1008 | Get Quote |
|
| 500MG | 2034 | Get Quote |
|
| 1G | Get Quote | Get Quote |
|
Biological Information
-
Product NamePBRM1-BD2-IN-7
-
NoteResearch use only, not for human use.
-
Brief DescriptionPBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM.
-
DescriptionPBRM1-BD2-IN-7, a selective and cell-active inhibitor targeting the polybromo-1 (PBRM1) bromodomain, demonstrates inhibitory efficacy against PBRM1-BD2 with an IC50 value of 0.29 μM. This compound is utilized in cancer research.
-
In Vitro——
-
In Vivo——
-
Synonyms——
-
PathwayChromatin/Epigenetic
-
TargetEpigenetic Reader Domain
-
RecptorEpigenetic Reader Domain
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number2819989-68-7
-
Formula Weight286.76
-
Molecular FormulaC16H15ClN2O
-
Purity>98% (HPLC)
-
Solubility——
-
SMILESO=C1C=2C(NC(N1)C3=C(C)C=CC=C3C)=CC=CC2Cl
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
molnova catalog
related products
-
OTX015
OTX015 is a potent BET bromodomain inhibitor with EC50 ranging from 10 to 19 nM for BRD2, BRD3, and BRD4. Phase 1.
-
GSK8573
GSK8573 is an inactive control compound for GSK2801. GSK8573 has binding activity to BRD9 (Kd of 1.04 μM).
-
Pocenbrodib
Pocenbrodib (FT-7051) is a potent inhibitor of the bromodomain of the CBP/p300 family with potential antitumour activity and is palatable for cancer research.
